论文部分内容阅读
[目的]研究NAP-2(73)蛋白在人肝癌细胞株SMCC-7721和人肝正常细胞株HL-7702的表达差异,并初步探讨NAP-2(73)对肝癌作用的相关机制。[方法]运用蛋白免疫印迹(WB)对NAP-2(73)在人肝癌细胞株SMCC-7721和人肝正常细胞株HL-7702中的表达情况进行再验证,RT-PCR法检测NAP-2(73)mRNA水平的表达。[结果]验证结果证实,在肝癌细胞株中NAP-2(73)呈阳性表达,而在正常肝细胞株中无表达。Real-timePCR结果显示肝癌细胞株中NAP-2(73)mRNA表达比正常肝细胞株增加了7倍。[结论]实验结果验证了初筛结果的可信性和生物信息学的分析和推测,提示NAP-2(73)可能是肝癌相关标志物。
[Objective] To investigate the differential expression of NAP-2 (73) protein in human hepatocellular carcinoma cell line SMCC-7721 and human liver normal cell line HL-7702 and to explore the mechanism of NAP-2 (73) [Method] The expression of NAP-2 (73) in human hepatocellular carcinoma cell line SMCC-7721 and human liver normal cell line HL-7702 was verified by Western blotting. The expression of NAP-2 (73) mRNA levels. [Results] The validation results confirmed that NAP-2 (73) was positive in HCC cell lines but not in normal liver cell lines. Real-time PCR results showed that NAP-2 (73) mRNA expression in HCC cell lines increased seven-fold compared with that of normal hepatocytes. [Conclusion] The experimental results verify the credibility of the preliminary screening results and bioinformatics analysis and speculation, suggesting that NAP-2 (73) may be related markers of liver cancer.